InvestorsHub Logo
Followers 4
Posts 276
Boards Moderated 0
Alias Born 02/23/2017

Re: Mistral post# 20529

Monday, 04/24/2017 12:43:51 PM

Monday, April 24, 2017 12:43:51 PM

Post# of 73287
Again, what is your argument? Because the only thing I see here is a successful product that works very well. The Addendum simply allows Viaderma to sell Viabecline (Otiko Product) which is a Phillips technology. But we have known this the entire time. So once again, the Patent was abandoned by Keough, Filled for by Otiko and Addendum was made allowing Viaderma to sell it and the Dr. hired Ivan to help quality control and bring it to the market. Everything is going according to plan. Am I missing something here??